Do analysts recommend BGLC or MRAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is BGLC or MRAI more profitable?

BioNexus Gene Lab has a net margin of -54.70% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat BioNexus Gene Lab's return on equity. Company Net Margins Return on Equity Return on Assets BioNexus Gene Lab -54.70% -37.43% -32.88% Marpai -85.70% N/A -100.23%

Do analysts rate BRTX or BGLC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend BMGL or BGLC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, BMGL or BGLC?

BioNexus Gene Lab has lower revenue, but higher earnings than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Basel Medical Group $8.90M 1.04 -$9.50M N/A N/A BioNexus Gene Lab $7.43M 0.54 -$2.98M -$1.48 N/A

Do analysts prefer ADVB or BGLC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Advanced Biomed 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend BGLC or ACON?

Aclarion has a consensus price target of $7.50, indicating a potential upside of 181.95%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than BioNexus Gene Lab. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

BioNexus Gene Lab (BGLC) Competitors

$1.67 -0.14 (-7.57%)

As of 09:52 AM Eastern

Compare

BGLC vs. MRAI, BRTX, BMGL, ADVB, and ACON

Should you buy BioNexus Gene Lab stock or one of its competitors? MarketBeat compares BioNexus Gene Lab with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioNexus Gene Lab include Marpai (MRAI), Biorestorative Therapies (BRTX), Basel Medical Group (BMGL), Advanced Biomed (ADVB), and Aclarion (ACON). These companies are all part of the "healthcare" industry.

How does BioNexus Gene Lab compare to Marpai?

BioNexus Gene Lab (NASDAQ:BGLC) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

BioNexus Gene Lab has a beta of 4.08, indicating that its share price is 308% more volatile than the broader market. Comparatively, Marpai has a beta of 4.92, indicating that its share price is 392% more volatile than the broader market.

In the previous week, BioNexus Gene Lab had 1 more articles in the media than Marpai. MarketBeat recorded 2 mentions for BioNexus Gene Lab and 1 mentions for Marpai. BioNexus Gene Lab's average media sentiment score of 1.43 beat Marpai's score of 0.50 indicating that BioNexus Gene Lab is being referred to more favorably in the media.

Company	Overall Sentiment
BioNexus Gene Lab	Positive
Marpai	Positive

BioNexus Gene Lab has a net margin of -54.70% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%
Marpai	-85.70%	N/A	-100.23%

18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 49.8% of Marpai shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by company insiders. Comparatively, 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

BioNexus Gene Lab has higher earnings, but lower revenue than Marpai. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$7.43M	0.54	-$2.98M	-$1.48	N/A
Marpai	$34.87M	0.51	-$28.75M	-$0.87	N/A

Summary

BioNexus Gene Lab and Marpai tied by winning 7 of the 14 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Biorestorative Therapies?

Biorestorative Therapies (NASDAQ:BRTX) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, BioNexus Gene Lab had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 2 mentions for BioNexus Gene Lab and 1 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 1.87 beat BioNexus Gene Lab's score of 1.43 indicating that Biorestorative Therapies is being referred to more favorably in the media.

Company	Overall Sentiment
Biorestorative Therapies	Very Positive
BioNexus Gene Lab	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biorestorative Therapies has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.08, suggesting that its stock price is 308% more volatile than the broader market.

BioNexus Gene Lab has a net margin of -54.70% compared to Biorestorative Therapies' net margin of -3,088.27%. BioNexus Gene Lab's return on equity of -37.43% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%

BioNexus Gene Lab has higher revenue and earnings than Biorestorative Therapies. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	24.42	-$14.24M	-$1.07	N/A
BioNexus Gene Lab	$7.43M	0.54	-$2.98M	-$1.48	N/A

Summary

BioNexus Gene Lab beats Biorestorative Therapies on 7 of the 13 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Basel Medical Group has a beta of 0.15, suggesting that its stock price is 85% less volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.08, suggesting that its stock price is 308% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Basel Medical Group had 5 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 7 mentions for Basel Medical Group and 2 mentions for BioNexus Gene Lab. BioNexus Gene Lab's average media sentiment score of 1.43 beat Basel Medical Group's score of 0.61 indicating that BioNexus Gene Lab is being referred to more favorably in the news media.

Company	Overall Sentiment
Basel Medical Group	Positive
BioNexus Gene Lab	Positive

BioNexus Gene Lab has lower revenue, but higher earnings than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	1.04	-$9.50M	N/A	N/A
BioNexus Gene Lab	$7.43M	0.54	-$2.98M	-$1.48	N/A

18.9% of BioNexus Gene Lab shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Basel Medical Group has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -54.70%. Basel Medical Group's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%

Summary

Basel Medical Group beats BioNexus Gene Lab on 6 of the 11 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Advanced Biomed?

Advanced Biomed (NASDAQ:ADVB) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

In the previous week, Advanced Biomed and Advanced Biomed both had 2 articles in the media. BioNexus Gene Lab's average media sentiment score of 1.43 beat Advanced Biomed's score of 0.45 indicating that BioNexus Gene Lab is being referred to more favorably in the news media.

Company	Overall Sentiment
Advanced Biomed	Neutral
BioNexus Gene Lab	Positive

Advanced Biomed has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -54.70%. Advanced Biomed's return on equity of 87.74% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Advanced Biomed	N/A	87.74%	64.49%
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%

BioNexus Gene Lab has higher revenue and earnings than Advanced Biomed. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Biomed	N/A	N/A	-$3.26M	$4.82	1.05
BioNexus Gene Lab	$7.43M	0.54	-$2.98M	-$1.48	N/A

18.9% of BioNexus Gene Lab shares are held by institutional investors. 27.0% of Advanced Biomed shares are held by company insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Advanced Biomed has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.08, indicating that its share price is 308% more volatile than the broader market.

Summary

Advanced Biomed beats BioNexus Gene Lab on 6 of the 11 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Aclarion?

BioNexus Gene Lab (NASDAQ:BGLC) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

BioNexus Gene Lab has higher revenue and earnings than Aclarion. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$7.43M	0.54	-$2.98M	-$1.48	N/A
Aclarion	$80K	81.80	-$7.23M	-$9.03	N/A

BioNexus Gene Lab has a net margin of -54.70% compared to Aclarion's net margin of -10,320.51%. BioNexus Gene Lab's return on equity of -37.43% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%
Aclarion	-10,320.51%	-54.41%	-51.71%

BioNexus Gene Lab has a beta of 4.08, indicating that its share price is 308% more volatile than the broader market. Comparatively, Aclarion has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Aclarion has a consensus price target of $7.50, indicating a potential upside of 181.95%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than BioNexus Gene Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by insiders. Comparatively, 0.0% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Aclarion had 1 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 3 mentions for Aclarion and 2 mentions for BioNexus Gene Lab. BioNexus Gene Lab's average media sentiment score of 1.43 beat Aclarion's score of 0.96 indicating that BioNexus Gene Lab is being referred to more favorably in the media.

Company	Overall Sentiment
BioNexus Gene Lab	Positive
Aclarion	Positive

Summary

BioNexus Gene Lab beats Aclarion on 10 of the 16 factors compared between the two stocks.

Get BioNexus Gene Lab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGLC vs. The Competition

Export

Metric	BioNexus Gene Lab	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.05M	$9.60B	$7.05B	$12.61B
Dividend Yield	N/A	1.62%	2.68%	8.00%
P/E Ratio	-1.13	26.00	27.10	24.26
Price / Sales	0.54	17.40	588.85	117.88
Price / Cash	N/A	14.81	29.22	49.36
Price / Book	0.47	6.05	10.85	6.29
Net Income	-$2.98M	$177.20M	$3.58B	$330.66M
7 Day Performance	-15.93%	-2.07%	-2.12%	-1.35%
1 Month Performance	-21.82%	6.96%	3.27%	-0.64%
1 Year Performance	-57.86%	11.42%	26.33%	19.08%

BioNexus Gene Lab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGLC BioNexus Gene Lab	0.9442 of 5 stars	$1.67 -7.6%	N/A	-65.8%	$4.05M	$7.43M	N/A	30	Positive News Short Interest Decrease Gap Down
MRAI Marpai	N/A	$0.64 -8.9%	N/A	-52.1%	$16.97M	$34.87M	N/A	150	Gap Down
BRTX Biorestorative Therapies	1.1558 of 5 stars	$0.35 -7.2%	N/A	-79.1%	$9.48M	$360K	N/A	7	Gap Down
BMGL Basel Medical Group	1.0535 of 5 stars	$6.22 +3.8%	N/A	-77.3%	$9.37M	$8.90M	N/A	36	News Coverage
ADVB Advanced Biomed	0.6282 of 5 stars	$5.04 -5.8%	N/A	N/A	$8.84M	N/A	1.05	40	Short Interest Increase Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGLC) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNexus Gene Lab (BGLC) Competitors

BGLC vs. MRAI, BRTX, BMGL, ADVB, and ACON

How does BioNexus Gene Lab compare to Marpai?

Summary

How does BioNexus Gene Lab compare to Biorestorative Therapies?

Summary

How does BioNexus Gene Lab compare to Basel Medical Group?

Summary

How does BioNexus Gene Lab compare to Advanced Biomed?

Summary

How does BioNexus Gene Lab compare to Aclarion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGLC vs. The Competition

BioNexus Gene Lab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNexus Gene Lab (BGLC) Competitors

BGLC vs. MRAI, BRTX, BMGL, ADVB, and ACON

How does BioNexus Gene Lab compare to Marpai?

Which has more volatility and risk, BGLC or MRAI?

Does the media prefer BGLC or MRAI?

Is BGLC or MRAI more profitable?

Do institutionals and insiders believe in BGLC or MRAI?

Do analysts recommend BGLC or MRAI?

Which has stronger earnings & valuation, BGLC or MRAI?

Summary

How does BioNexus Gene Lab compare to Biorestorative Therapies?

Do insiders and institutionals have more ownership in BRTX or BGLC?

Does the media prefer BRTX or BGLC?

Do analysts rate BRTX or BGLC?

Which has more risk and volatility, BRTX or BGLC?

Is BRTX or BGLC more profitable?

Which has preferable valuation and earnings, BRTX or BGLC?

Summary

How does BioNexus Gene Lab compare to Basel Medical Group?

Which has more risk and volatility, BMGL or BGLC?

Do analysts recommend BMGL or BGLC?

Does the media favor BMGL or BGLC?

Which has higher valuation & earnings, BMGL or BGLC?

Do insiders & institutionals believe in BMGL or BGLC?

Is BMGL or BGLC more profitable?

Summary

How does BioNexus Gene Lab compare to Advanced Biomed?

Does the media prefer ADVB or BGLC?

Is ADVB or BGLC more profitable?

Which has preferable earnings & valuation, ADVB or BGLC?

Do insiders and institutionals believe in ADVB or BGLC?

Do analysts prefer ADVB or BGLC?

Which has more risk and volatility, ADVB or BGLC?

Summary

How does BioNexus Gene Lab compare to Aclarion?

Which has stronger earnings & valuation, BGLC or ACON?

Is BGLC or ACON more profitable?

Which has more risk & volatility, BGLC or ACON?

Do analysts recommend BGLC or ACON?

Do institutionals and insiders have more ownership in BGLC or ACON?

Does the media favor BGLC or ACON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGLC vs. The Competition

BioNexus Gene Lab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools